Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2382 • 2019 ACR/ARP Annual Meeting
Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
Paul Emery¹, Ferdinand Breedveld ², Ronald Pedersen ³, Eduardo Jose Campos ⁴, Annette Szumski ⁵ and Tomohiro Hirose ⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Leids Universitair Medisch Centrum, Leiden, Netherlands, ³Pfizer, Collegeville, ⁴Pfizer Japan Inc, Toyko, Japan, ⁵Syneos Health, Princeton, NJ
Background/Purpose: For patients with rheumatoid arthritis (RA) who are treated with etanercept (ETN) plus methotrexate (MTX), dosing down of ETN or withdrawal of MTX are…
Abstract Number: 2383 • 2019 ACR/ARP Annual Meeting
Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
Yuji Yoshioka¹, Shouhei Nagaoka ² and Hiroyuki Hagiyama ³, ¹Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan, ²Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ³Yokohama City Minato Red Cross Hospital, Yokohama
Background/Purpose: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is important complication in the rheumatoid arthritis (RA) treatment. There were few reports about clinical features of MTX-LPD and RA…
Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Maya H. Buch¹, Bara Erhayiem², Graham Fent², Paul Baxter³, Elizabeth M.A. Hensor⁴, Adam McDiarmid², Peter Swoboda⁵, Ananth Kidambi², David Ripley², Pankaj Garg², Sarah Horton⁴, Raluca Bianca Dumitru⁴, Kamran Naraghi⁴, John Greenwood⁶, Paul Emery⁷, Sue Pavitt⁸ and Sven Plein², ¹Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁸Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
Abstract Number: 571 • 2018 ACR/ARHP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
Aaron Broadwell¹, Vance Bray², Douglas Conaway³, Joy Schechtman⁴, Alan J. Kivitz⁵, Dennis Parenti⁶, Shawn Black⁶, Stephen Xu⁷, Wayne Langholff⁷ and Shelly Kafka⁶, ¹Rheumatology Osteoporosis Specialists, Shreveport, LA, ²Denver Arthritis Clinic, Denver, CO, ³Carolina Health Specialists, Myrtle Beach, SC, ⁴Sun Valley Arthritis Center, Peoria, AZ, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Takeshi Suzuki, Takayasu Ando, Shoshi Shinagawa, Machiko Mizushima, Tomohiko Shibata and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…
Abstract Number: 616 • 2018 ACR/ARHP Annual Meeting
Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
Pamela B. Rosenthal¹, Jeffrey S. Berger² and Bruce N. Cronstein¹, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Low dose weekly MTX remains the anchor drug for treatment of Rheumatoid Arthritis. The principal mechanism by which MTX suppresses inflammation in Rheumatoid Arthritis…
Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 622 • 2018 ACR/ARHP Annual Meeting
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
Janet E. Pope¹, Emmanouil Rampakakis², Julie Vaillancourt², Eric Grant³, Louis Bessette⁴, Juris Lazovskis⁵, Boulos Haraoui⁶ and John S. Sampalis⁷, ¹Department of Medicine, University of Western Ontario, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Private Practice, Saint John, NB, Canada, ⁴Laval University, Québec, QC, Canada, ⁵Riverside Professional Centre, Sydney, NS, Canada, ⁶Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ⁷McGill University, Montreal, QC, Canada
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either…
Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Josef S. Smolen¹, Stanley Cohen², Paul Emery³, William F C Rigby⁴, Yoshiya Tanaka⁵, Ying Zhang⁶, Alan Friedman⁶, Ahmed A. Othman⁶, Heidi S. Camp⁶ and Aileen L. Pangan⁶, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Metroplex Clinical Research Center, Dallas, TX, ³Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, ⁴Dartmouth College, Hanover, NH, ⁵Univ of Occupational and Environmental Health, Kitakyushu, Japan, ⁶AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…
Abstract Number: 1065 • 2018 ACR/ARHP Annual Meeting
Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
Jian-Da Ma¹, Jun Jing¹, Jun-Wei Wang¹, Tao Yan², Yun-Shan Mou², Ying-Qian Mo¹ and Lie Dai¹, ¹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ²Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Fibroblast-like synoviocytes (FLS) play important roles on joint destruction in rheumatoid arthritis (RA). Recent reports showed that antimalaria drug artesunate presents anti-cancer potential by…
Abstract Number: 1540 • 2018 ACR/ARHP Annual Meeting
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Debbie Olsson-White¹, John Olynyk^2,3, Warren Raymond^4,5, Shereen Paramalingam^1,5 and Helen Keen^1,6, ¹Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, ²Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, Australia, ³School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁴Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia, ⁵University of Western Australia, Crawley, Australia, ⁶University of Western Australia, Perth, Australia
Background/Purpose: MTX is the cornerstone of treatment of RA. A relatively rare side effect is liver fibrosis and cirrhosis, the incidence in patients on long-term…
Abstract Number: 2036 • 2018 ACR/ARHP Annual Meeting
Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Ankita Singh¹, Ramnath Misra² and Amita Aggarwal², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Methotrexate (MTX) is first line of therapy to treat Rheumatoid Arthritis (RA) patients and one third of patients do not respond to this drug.…
Abstract Number: 2460 • 2018 ACR/ARHP Annual Meeting
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Yoshihiko Ikeno¹, Youkou Kobayashi², Ikuo Akutsu³, Hirokuni Hirata⁴, Masafumi Arima⁵ and Kazuhiro Kurasawa⁶, ¹Rheumatology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ²Hematology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ³Respiratory and allergy, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ⁴Respiratory and allergy, Dokkyo Medical University Saitama Medical center, Saitama, Japan, ⁵Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan, ⁶Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) was first reported in 1991. The symptom is known to spontaneously regress after suspending the use of MTX, suggesting its…
Abstract Number: 289 • 2018 ACR/ARHP Annual Meeting
Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
Nizar Abdulateef Al Ani¹, Faiq Isho Gorial¹, Eman Khedir², Ahmed Hussein², Yasser El Dershaby³ and Ali AlJabban⁴, ¹Baghdad Teaching Hospital, College of Medicine, Baghdad University, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad University, Baghdad, Iraq, ³Pfizer, Dubai, United Arab Emirates, ⁴Pfizer, Baghdad, Iraq
Background/Purpose: Real-world data on adherence to TNFα inhibitors in patients with RA are missing from many regions, including the Middle East. This study evaluated the…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].